Research & Studies
Share your love
Link Between Proteins in Tears and Pain After Eye Surgery
In a study published in the Journal of Proteome Research, researchers from Oregon Health & Science University (OHSU) have identified a connection between specific proteins found in patients’ tears and persistent pain experienced months after eye surgery. This discovery could…
Nicox Concludes U.S. Recruitment for Phase 3 NCX 470 Trial
Nicox announced the recruitment and randomization of the final patient in the United States for its Denali Phase 3 trial of NCX 470. This milestone marks a significant step in evaluating the safety and efficacy of NCX 470 for patients…
Bausch + Lomb Acquires Trukera Medical
Bausch + Lomb has completed the acquisition of Trukera Medical, a US-based ophthalmic medical diagnostic company. The financial details of the acquisition were not disclosed. Trukera Medical’s Innovative ScoutPro Device Trukera Medical, previously owned by private equity firm AccelMed Partners…
Oertli Receives FDA Clearance for Faros Anterior System
Oertli Instrumente AG announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its globally established Faros anterior cataract surgery system. This milestone underscores Oertli’s expansive global presence and unwavering commitment to delivering advanced and reliable…
Topcon and Orbis Partner to Expand DR Screening in Rwanda
Topcon Healthcare, in collaboration with Orbis International and the Rwanda International Institute of Ophthalmology (RIIO), has embarked on an initiative to enhance diabetic retinopathy screening in Rwanda. Donation of Robotic Retinal Cameras To facilitate this effort, Topcon has generously donated…
Trial Results for Susvimo Show Sustained Efficacy in DME and DR
Genentech and Roche released compelling 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL, marking a significant development in the treatment landscape for diabetic macular edema (DME) and diabetic retinopathy (DR). Reintroduction of…
Okyo Pharma’s Phase 2 Trial for Neuropathic Corneal Pain
Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…
Opthea Forms Medical Advisory Board with Global Retina Experts
Opthea announced the formation of its Medical Advisory Board (MAB), comprised of ten distinguished thought leaders in the field of retina from across the globe. The board includes experts from the United States, Argentina, Australia, China, France, Germany, and Israel,…
NexThera Submits IND Application for NT-101 for Wet AMD
NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…
Funding Boost for PulseMedica’s Eye Floater Technology
PulseMedica has successfully raised a total of $12 million in their recent pre-Series A financing round, marking a significant milestone in their pursuit of innovative eye floater diagnostic and treatment technologies. Accelerating Clinical Validation and Expansion Efforts This funding round…